Drug Profile

EB 104

Alternative Names: EB-104

Latest Information Update: 02 Feb 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Estrella Immunopharma
Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Preclinical Diffuse large B cell lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma

02 Feb 2025 Preclinical trials in Diffuse large B cell lymphoma in USA (Parenteral) prior to January 2025 (Estrella Immunopharma Pipeline, January 2025)
02 Feb 2025 Preclinical trials in Precursor cell lymphoblastic leukaemia-lymphoma in USA (Parenteral) prior to January 2025 (Estrella Immunopharma Pipeline, January 2025)
03 Oct 2022 Early research in Diffuse large B cell lymphoma in USA (Parenteral)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com